CRISPR Therapeutics AG — Director's Dealing 2018

May 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-05-17

Reporting Person: Novak Rodger (Director, President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-17	Common Shares	M	35240	$1.81	Acquired	1183247	Direct
2018-05-17	Common Shares	M	39760	$14.00	Acquired	1223007	Direct
2018-05-17	Common Shares	S	75000	$60.00	Disposed	1148007	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-05-17	Stock Option (Right to Buy)	$1.81	M	35240	Disposed	2025-09-10	Common Stock (35240)	Direct
2018-05-17	Stock Option (Right to Buy)	$14.00	M	39760	Disposed	2016-10-18	Common Stock (39760)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31equal monthly installments thereafter.

F3: This option was granted on October 18, 2016 with respect to 200,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.